Materialise NV

Thank you for standing by and welcome to the third quarter 2026 materialized NV financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question, you will need to press star 1 1 on your telephone. You will then hear a message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. Now it's my pleasure to turn the call to Jodi Borfering, Managing Director at Alliance Investor Relations. Please proceed.

Thank you, Carmen, and thank you for joining us today for MaterialEye's quarterly conference call. With us on the call are Brigitte de Vet, Chief Executive Officer, and Koen Berges, Chief Financial Officer. Today's call and webcast are being accompanied by a slide presentation that reviews Materialise's strategic financial and operational performance for the third quarter of 2026. To access the slides, if you have not already done so, please go to the investor relations section of the company's website at www.materialise.com. The earnings press release that was issued earlier today can be found on that page. Before we get started, I would like to remind you that management may make forward-looking statements regarding the company's plans, expectations and growth prospects, among other things. These forward-looking statements are subject to known and unknown uncertainties and risks that could cause actual results to differ materially from the expectations expressed, including competitive dynamics and industry change. Any forward-looking statements, including those related to the company's future results and activities, represent management's estimates as of today and should not be relied upon as representing their estimates as of any subsequent day. Management disclaims any duty to update or revise any forward-looking statements to reflect future changes or events and expectations. A more detailed description of the risks and uncertainties and other factors that may impact the company's future business or financial results can be found in the company's most recent annual report on form 20F filed with the FCC. Finally, management will discuss certain non-IFRS measures on today's conference call. A grant conciliation table is contained in the earnings release and at the end of the slide presentation. With that, I would now like to turn the call over to Brigitte de Vet. Brigitte?

Good morning and good afternoon, and thank you all for joining us today. You can find the agenda for our call on slide three. First, I will summarize the business highlights for the third quarter of 2026. Then I will pass the floor to Koen, who will take you through the third quarter of financials. And finally, I will come back and explain what we expect the remaining months of 2026 to bring. When we've completed our prepared remarks, we'll be happy to respond to questions. Moving to slide four for the highlights of the third quarter 2026. In the third quarter, we continue to execute on our strategic priorities across all business segments. In medical, we see real momentum in the demand for personalized solutions in various clinical fields, and we have accelerated our investments to scale the adoption of personalization. In the third quarter in particular, we have made progress in our current focus segments. First, in our medical CMF business, we signed an agreement with the Superhuman Center in Ukraine to support the growing need for cranio-maxillofacial reconstructive surgery resulting from the ongoing war. The agreement will enable us to support the treatment of hundreds of patients and war victims with patient-specific solutions and standard plates. Beyond providing surgical solutions, we will support the development of local medical expertise by providing access to our software ecosystem and by providing specialist training at medical universities in Kiev and Lviv, focusing on 3D visualization and patient-specific surgical planning. For Materialise, this partnership demonstrates how we can combine our technology and clinical expertise to address complex reconstructive needs while helping build local capabilities for more personalized care. In the third quarter, we also launched several new products in our CMS segment, demonstrating Our continued focus on making personalized surgical solutions more accessible and easier to integrate into routine clinical practice. As an example, we introduced ready-to-use sterile packaging. These solutions help hospitals reducing operating room preparation steps and enhance compliance with regulatory requirements. We also introduced the next version of mimics and light CMF. which gives clinical teams greater autonomy in 3D surgical planning. Surgeons can now prepare and review their own 3D plans or rely on our clinical engineers to plan their cases when needed. All of this in an integrated workflow. These innovations reflect our strategy to improve efficiency for healthcare providers and support the broader scaling of our CMS solutions. Second, In our medical cardiac business, we expanded our AI-powered mimics planning solutions for cardiac interventions with a new workflow for transcatheter aortic valve replacement procedures. These procedures involve replacing a previously implanted aortic valve that is no longer functioning properly. This is a more complex intervention than an initial valve replacement, and the procedure requires careful navigation and planning. The new AI-powered workflow automates several critical planning steps, helping clinicians assess potential risks and reduce manual effort, while maintaining full control over clinical decisions. The introduction of this functionality reflects our continued focus on making complex interventions more predictable and efficient, to advance 3D planning and AI-powered automation. Third, in our medical soft tissue business, we expanded materialized mimics for thoracic surgery and now offer a dedicated workflow for liver resection planning and interoperative support. Liver resections, primarily performed to remove tumors, present significant clinical challenges. Surgeons must meticulously balance adequate tumor margins while preserving enough healthy tissue to prevent postoperative liver failure. Our new workflow assists surgeons in critical clinical decision-making, allowing them to identify anatomical risks and confidently plan the procedure. This strategic expansion directly addresses the growing demand for advanced 3D planning and intraoperative support in minimally invasive surgeries. and it is the next step to build out our comprehensive portfolio of 3D planning solutions for soft tissue cancer resections. Turning to our software segment now. In the third quarter, we continue to see encouraging commercial momentum for our CoEM platform. First, we closed strategic deals for CoEM NPI with leading customers in our focus segments and in particularly aerospace industry. CoEM NPI is one of our three CoEM offerings designed to accelerate new product introductions and qualification processes for series additive manufacturing. By streamlining critical steps, we help customers move more efficiently from product development to qualified series production. Second, we further strengthened our CoEM platform by integrating CoEM bricks with identified 3D, our technology for securing and tracing digital part files, throughout the manufacturing process. While security controls previously applied to an entire 3D printing build, we can now manage protection, traceability, and users rights at the level of each individual part, even when multiple parts from different owners are produced in the same build. For customers in industries with complex supply chains and strict compliance requirements, including defense, This enables secure on-demand production across multiple locations with full control over intellectual property and production rights. Third, we are gearing up for Formnext, the world's leading additive manufacturing trade show, where we'll showcase the power of an open ecosystem approach and we'll demonstrate how the materialized CoEM ecosystem helps manufacturers build connected, scalable EM operations. The day before Formnext, We will also play a leading role at the AM Innovation and Standards Summit, advocating for common frameworks to scale additive manufacturing as a strategic capability. And in addition, at the Formnext European Defence event, we will demonstrate how we can play a distinctive role providing manufacturing capacity and the digital infrastructure needed to connect and manage production across secure, distributed production environments. Moving on to manufacturing. In the third quarter, we continue to see strong momentum in core manufacturing with revenues for series production growing by more than 30% year over year in the quarter, driven by demand from the aerospace, semiconductor, and defense industries. In the third quarter, we also invested in additional metal additive manufacturing capabilities in order to enable faster production of larger metal components, particularly for demanding defense applications. The investment will also support our research into software-based quality assurance by providing valuable production data to develop and validate more reliable methods for assessing the quality of aerospace parts. This will be a critical contribution to the European Sunvisa project. As you might recall, we are a leading partner in this European research initiative focusing on improving and standardizing quality assurance for metal 3D printed aerospace components. Our materialized motion business also showed strong momentum for our new insults called FITS Dynaprint, our affordable orthotics solution that we recently launched in the US to a limited set of centers. FITS Dynaprint gives clinicians greater choice and flexibility with faster delivery times of the insults and without the need to invest in their own 3D printer. Since its introduction, we have seen a significant increase in adoption supported by very positive feedback from customers, including podiatrists. In the UK and Ireland, where FitzDynaprint was first launched, we have seen volumes double. With the expansion into North America in the third quarter, total volumes have now tripled versus the second quarter, reflecting strong market adoption and growing demand for the solution. Turning over to Koen now, who will present the financial results.